Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
We describe the progress towards developing a patient rated toxicity index that meets all of the patient-important attributes defined by the OMERACT Drug Safety Working Party. These attributes are frequency, severity, importance to patient, importance to the clinician, impact on economics, impact on activities, and integration of adverse effects with benefits. The Stanford Toxicity Index (STI) has been revised to collect all attributes with the exception of impact on activities. However, since the STI is a part of the Health Assessment Questionnaire (HAQ), impact on activities is collected by the HAQ. In particular, a new question asks patients to rate overall satisfaction, taking into consideration both benefits and adverse effects. The next step in the development of this tool is to ensure that the STI meets the OMERACT filter of truth, discrimination, and feasibility. Although truth and feasibility have been confirmed by comparisons within the ARAMIS database, discrimination needs to be assessed in clinical trials.
Welch
V
V
Clinical Epidemiology Unit, Loeb Research Institute, Ottawa, Ontario, Canada. vwelch@lri.ca
Singh
G
G
Strand
V
V
Fries
J
J
Boers
M
M
Ramey
D
D
Day
R O
RO
Brooks
P
P
Tugwell
P
P
Clinch
J
J
Kristjansson
B
B
D016907:Adverse Drug Reaction Reporting Systems / Q000639:trends*; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000633:toxicity*; D002986:Clinical Trials as Topic / Q000592:standards*; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012219:Rheumatology / Q000592:standards; D011795:Surveys and Questionnaires / Q000592:standards
D018501:Antirheumatic Agents